NetSpend Holdings (NASDAQ:PACB) sells an integrated platform that allows for genetic analysis. The company currently markets a technology system called SMRT which can analyze DNA in real time. The initial goal is to allow scientists to quickly sequence the DNA of individuals, however, the company hopes to expand its technology to include the ability to experiment with chemical and structural changes to the DNA. 
Pacific Biosciences is currently focused on its DNA sequencing tool. However, the company expects to develop and launch additional applications which would build on the platform. These addons would allow scientists to analyze RNA, protein, as well as experiment with the effects of alterations. The company plans to use the real time analysis technology to improve the speed at which such scientific analysis takes place. 
The company's initial public offering of stock on the NASDAQ occurred on October 26, 2010. The company offered 12.5M shares each for $16. This was within the initial price range of $15-$17. The IPO raised a total of $200M. The lead underwriters of the deal were J P Morgan Chase (JPM) and Morgan Stanley (MS).
Pacific Biosciences has accumulated approximately $255M in debt over the course of its operations. The IPO will both fund the debt as well as pay for future Research and Development Expense.  While the company has not experienced significant revenues yet, it does have an order backlog of approximately $15M. These consist of orders which have been placed and are in the process of being fulfilled.